A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Summary
- Eligibility
- for people ages 18-130 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- ID
- NCT05061134
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 195 study participants
- Last Updated